跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 48 条关于
“hyperinflammation”
全部
48
临床试验
17
药物
0
机构
0
资讯
31
去年
SeaStar Medical Focuses on Hyperinflammation Therapies for Critical Illnesses
去年
FDA Approves Gamifant as First Treatment for Macrophage Activation Syndrome in Still's Disease
去年
SeaStar Medical Advances AKI Trial with New Site Activations and Enrollment Milestones
去年
SeaStar Medical's AKI Trial Gains Momentum with Stanford Enrollment and Milestone Achievement
去年
FDA Approves SeaStar Medical's SCD-ADULT Feasibility Study for Cardiorenal Syndrome
去年
SeaStar Medical's SCD Therapy Receives $2 Million DoD Grant for Military Burn and Sepsis Research
去年
FDA Grants Priority Review for Gamifant in HLH/MAS Associated with Still's Disease
去年
AB2 Bio and Nippon Shinyaku Strike $686M Deal for Rare Disease Drug Tadekinig Alfa
去年
Sobi Launches Phase 2a Trial of Gamifant for Interferon-Gamma-Driven Sepsis
去年
SeaStar Medical Reaches Halfway Enrollment Milestone in Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury
第 1 页,共 4 页
上一页
下一页